DarDoc Research

GLP-1 Trial & Approval Tracker

Compare GLP-1 trial arms

Compare results within a trial or inspect the context behind results from different studies.

REDEFINE 1

CagriSemaWegovy injection

Without diabetes · 68 weeks · n=3,417

Double-blind, active- and placebo-controlled. Treatment-policy estimand.

Mean body weight change at 68 weeks
  • CagriSema 2.4 mg / 2.4 mg−20.4%
  • Semaglutide 2.4 mg−14.9%
  • Cagrilintide 2.4 mg−11.5%
  • Placebo−3.0%
Published paper PubMed abstract NCT05567796

A direct comparison uses arms from the same trial. Switch to Two studies to inspect the context behind separate results.